Affiliation:
1. Leonard Wolfson Experimental Neurology Centre The National Hospital for Neurology and Neurosurgery London UK
2. Royal Free Hospital, Royal Free London NHS Foundation Trust London UK
3. UCL Queen Square Institute of Neurology London UK
4. Homerton University Hospital NHS Foundation Trust London UK
5. The National Hospital for Neurology and Neurosurgery London UK
6. The North Middlesex University Hospital London UK
Abstract
AbstractNew‐onset refractory status epilepticus (NORSE) is a devastating neurological presentation. There is a paucity of large studies on NORSE as it is a relatively new clinical syndrome. The aim of this review was to summarize the etiologies and establish a mortality rate for NORSE. Two independent authors systematically searched the following electronic databases from January 1, 2005 April 20, 2021: PubMed, Embase, OVID, Scopus, Web of Science, “Clinicaltrials.gov,” and the International Standard Randomised Controlled Trial Number (ISRCTN) registry. We included all primary research studies of NORSE in adults and excluded commentaries, reviews, pre‐clinical studies, and pediatric populations. Etiology was extracted from all studies meeting eligibility criteria, whereas data relating to treatments, hospital stay, functional outcomes, and mortality were extracted from studies with sample size ≥5. We conducted a random‐effects meta‐analysis of mortality rate with meta‐regression testing for significant covariates. Of 1482 studies, 109 case reports and case series met our criteria, comprising 395 cases of NORSE. The most common etiology was cryptogenic in 197 cases (49.9%), followed by autoimmune in 143 cases (36.2%). The pooled mortality rate was 22% (95% confidence interval 17%–27%; = 15), with low heterogeneity ( = 0%). Meta‐regression revealed that year of study, treatment with ketogenic diet or immunotherapy, percentage of cryptogenic cases, and length of intensive care unit stay were not significant covariates for mortality. Common treatments included antiseizure medications (median 5), general anesthesia, and immunotherapy such as corticosteroids, intravenous immunoglobulin, and plasma exchange. Mean length of intensive care admission was 33.4 days, with 52% of cases diagnosed with epilepsy on discharge. Neurocognitive impairment was a common sequela of NORSE. NORSE is associated with a high mortality. Half of cases remain cryptogenic, which presents a diagnostic challenge. Future focus should be on elucidating the underlying neurobiology and determining the most effective therapeutic interventions.
Subject
Neurology (clinical),Neurology
Reference75 articles.
1. The NORSE (new‐onset refractory status epilepticus) syndrome: defining a disease entity;Wilder‐Smith EPV;Ann Acad Med Singap,2005
2. Continuous EEG findings in autoimmune encephalitis;Moise A‐M;J Clin Neurophysiol,2021
3. Cryptogenic NORSE
4. Frequency and Prognosis of Convulsive Status Epilepticus of Different Causes
5. A presentation of new onset refractory status epilepticus (NORSE) secondary to newly diagnosed neurosyphilis‐a case report;Murphy R;Ir J Med Sci,2020
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献